Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2020

View Archived Issues

Minimal phenotyping gives minimal insights into MDD genetics

Stopping tau in its tracks

Phase IIa study of golexanolone shows no clinical benefit

FDA approves the initiation of stem cell study for protection against COVID-19

CellCentric enters agreement with PCCTC for phase II dose-expansion study of CCS-1477

Catalyst announces pivotal phase III design for MarzAA

Researchers in Montreal and NYU partner on new COVID-19 clinical study

IXT-v100 vaccine decreases meth-taking and -seeking behaviors in vivo

Preclinical data support development of WZ-66 for NASH

Roche patents Toll-like receptor antagonists

Beijing Yuezhikangtai Biomedicines discloses VEGFR inhibitors

Forge Therapeutics presents new bacterial LpxC inhibitors

Investigator-initiated IND application filed to study CORVax12 to prevent COVID-19

New USP9X inhibitors identified by FORMA Therapeutics

Biogen describes new OGA inhibitors

New nitrofuran-class antibiotic IITR-06144 shows efficacy against resistant bacteria

FDA clears Polaryx's IND for PLX-200 in juvenile neuronal ceroid lipofuscinosis

Emapalumab and anakinra studied to reduce hyperinflammation and respiratory distress in COVID-19

Kolon begins first-in-human study of KLS-2031 for neuropathic pain from lumbosacral radiculopathy

Selective circadian regulation may yield new therapies

New HDAC6 inhibitors show promise in Charcot-Marie-Tooth disease cell model

GPR56 found to be tied with antidepressant treatment response

Viriom opens phase II study of NNRTI elsulfavirine for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...